A detailed history of Capital Investment Counsel, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital Investment Counsel, LLC holds 56,071 shares of GILD stock, worth $5.18 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares
56,071
Previous 54,354 3.16%
Holding current value
$5.18 Million
Previous $3.73 Billion 26.06%
% of portfolio
0.81%
Previous 0.73%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$66.59 - $83.99 $114,335 - $144,210
1,717 Added 3.16%
56,071 $4.7 Billion
Q2 2024

Aug 14, 2024

BUY
$63.15 - $72.88 $94,282 - $108,809
1,493 Added 2.82%
54,354 $3.73 Billion
Q1 2024

Aug 14, 2024

BUY
$71.58 - $87.29 $1.18 Million - $1.44 Million
16,536 Added 45.52%
52,861 $3.87 Billion
Q4 2023

Aug 14, 2024

BUY
$73.27 - $83.09 $2.66 Million - $3.02 Million
36,325 New
36,325 $2.94 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Capital Investment Counsel, LLC Portfolio

Follow Capital Investment Counsel, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Investment Counsel, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Investment Counsel, LLC with notifications on news.